The most frequent grade ≥ 3 AEs were myelosuppression, weakness and nausea/vomiting when Endostar was used to treat patients with NSCLC after first-line EGFR-TKI therapy failure. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.